Kehrl J H, Fauci A S
J Clin Invest. 1983 Apr;71(4):1032-40. doi: 10.1172/jci110830.
The in vivo and in vitro immune response after in vivo immunization with pneumococcal polysaccharides (PPS) has been analyzed in man. Substantial differences were noted in this system when compared with human responses to soluble protein antigens. Within 6 d after immunization, specific PPS antigen-binding cells (ABC), specific plaque-forming cells (PFC), and cells capable of spontaneously synthesizing in vitro large amounts of specific anti-PPS immunoglobulin (Ig) G. IgA, and lesser amounts of specific IgM appeared in the peripheral blood. The ABC, PFC, and the total amount of specific spontaneous antibody production followed nearly identical kinetics after immunization. Low doses of irradiation markedly inhibited spontaneous anti-PPS antibody production by lymphocytes obtained 7 or 8 d after immunization, suggesting a requirement for in vitro proliferation for full expression of antibody-secreting capability of these cells that are activated in vivo and are capable of spontaneous antibody production in vitro. Spontaneous secretion by B lymphocytes in vitro was independent of T cells, unmodified by the addition of T cell factors, and readily suppressible by pokeweed mitogen (PWM). By 2 wk after immunization, spontaneous anti-PPS antibody production in vitro was no longer detected. Subsequent stimulation of lymphocytes in culture with a wide range of concentrations of specific antigen did not trigger either proliferation or specific antibody synthesis. Despite the unresponsiveness of these cells to antigenic stimulation at this time, they were capable of specific antiPPS antibody production after stimulation with PWM. In vivo booster immunization 4 mo after an initial immunization did not reproduce the increased numbers of ABC, PFC, or in vitro specific antibody production that had been found 4 mo earlier. The dichotomy in capacity for activation of PPS-specific B cells by PWM vs. specific antigen, and the in vivo and in vitro unresponsiveness to in vivo booster immunization with PPS, contrast sharply with previous studies in man with soluble protein antigens such as keyhole limpet hemocyanin and tetanus toxoid. Furthermore, the lack of T cell activation by PPS also contrasts with previous results with tetanus toxoid and other protein antigens. This system should prove useful in delineating certain aspects of human B cell physiology not readily approachable with standard soluble protein antigens.
对人体接种肺炎球菌多糖(PPS)后的体内和体外免疫反应进行了分析。与人体对可溶性蛋白抗原的反应相比,该系统存在显著差异。免疫后6天内,外周血中出现了特异性PPS抗原结合细胞(ABC)、特异性空斑形成细胞(PFC)以及能够在体外自发大量合成特异性抗PPS免疫球蛋白(Ig)G、IgA和少量特异性IgM的细胞。免疫后,ABC、PFC以及特异性自发抗体产生的总量遵循几乎相同的动力学。低剂量辐射显著抑制免疫后7或8天获得的淋巴细胞自发产生抗PPS抗体,这表明这些在体内被激活且能够在体外自发产生抗体的细胞,其抗体分泌能力的充分表达需要体外增殖。B淋巴细胞在体外的自发分泌独立于T细胞,不受T细胞因子添加的影响,且易被商陆有丝分裂原(PWM)抑制。免疫后2周,体外不再检测到自发抗PPS抗体产生。随后用多种浓度的特异性抗原刺激培养中的淋巴细胞,既未引发增殖也未引发特异性抗体合成。尽管此时这些细胞对抗抗原刺激无反应,但在用PWM刺激后它们能够产生特异性抗PPS抗体。初次免疫4个月后进行体内加强免疫,并未重现4个月前发现的ABC、PFC数量增加或体外特异性抗体产生增加的情况。PWM与特异性抗原激活PPS特异性B细胞的能力二分法,以及对PPS体内加强免疫的体内和体外无反应性,与之前人体对可溶性蛋白抗原(如钥孔戚血蓝蛋白和破伤风类毒素)的研究形成鲜明对比。此外,PPS缺乏T细胞激活也与破伤风类毒素和其他蛋白抗原的先前结果形成对比。该系统应有助于阐明人体B细胞生理学的某些方面,而这些方面用标准可溶性蛋白抗原不易研究。